drugset
drugset / Trial / NCT07816315

Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

NCT07816315 ↗

Phase 3 Not yet recruiting 500 enrolled Ollin Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).

Timeline

Start
2026-10-15
Primary completion
2028-12-15
Completion
2029-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic — Intravitreal
Subject OLN324 Unknown — Intravitreal

Indications

wet macular degeneration